Wen‐Feng Fang

机构：Hohai University, Chinese Academy of Medical Sciences & Peking Union Medical College, Xinjiang Institute of Materia Medica, Shanghai Institute of Materia Medica

发表论文 268 篇 · 总被引 6191 次 · h-index 40

代表论文

• A B7H3-targeting antibody–drug conjugate in advanced solid tumors: a phase 1/1b trial (2025 · Nature Medicine · 被引 88)
• Sacituzumab tirumotecan versus docetaxel for previously treated EGFR -mutated advanced non-small cell lung cancer: multicentre, open label, randomised controlled trial (2025 · BMJ · 被引 41)
• Sacituzumab tirumotecan (sac-TMT) in patients (pts) with previously treated advanced EGFR-mutated non-small cell lung cancer (NSCLC): Results from the randomized OptiTROP-Lung03 study. (2025 · Journal of Clinical Oncology · 被引 10)
• HS-10375, a selective EGFR C797S tyrosine kinase inhibitor, in advanced non–small cell lung cancer (2025 · Journal of Translational Medicine · 被引 8)
• Phase I study of iza-bren (BL-B01D1), an EGFR x HER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic small cell lung cancer (SCLC). (2025 · Journal of Clinical Oncology · 被引 8)
• Chemotherapy-Based Combination Regimens for Advanced EGFR-Mutant NSCLC After EGFR-TKI Failure: A Network Meta-Analysis (2025 · Journal of the National Comprehensive Cancer Network · 被引 7)